Morgan Stanley Sees Brighter View on 2016 Emerging for Stryker Corporation

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $105.00 price target on

. In the report, Morgan Stanley noted, "Our discussions with management at AAOS struck a bullish tone and pointed to an inflection coming over the next 12 months. We see opportunities to (i) gain share in Europe, specifically in MedSurg, (ii) drive Mako adoption following recent momentum and approvals, (iii) grow sports med and extremities through recent product additions,and (iv) build on emerging market progress through Trauson geographic expansion. Additionally, Stryker's balance sheet remains a flexible growth driver even as the SNN debate fades." Stryker Corporation closed on Thursday at $91.53.